Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.44 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 9/20 | 0.41 |
| ▸ | JAK2 | O60674 | 7/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.39 |
| ▸ | MERTK | Q12866 | 3/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 3/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2330729 | 0.86 | USP30 (0.58) | BTKEGFRUSP30 | |
| SCHEMBL2330725 | 0.86 | USP30 (0.58) | BTKEGFRUSP30 | |
| SCHEMBL2332984 | 0.83 | CHEK2 (0.49) | IRAK1IRAK4JAK3JAK2 | |
| SCHEMBL3434611 | 0.81 | KMT2A (0.56) | BTKEGFRITK | |
| SCHEMBL3190443 | 0.81 | KMT2A (0.39) | JAK3JAK2BTK | |
| SCHEMBL2334905 | 0.81 | ABL1 (0.41) | JAK3JAK2SPRBTK | |
| SCHEMBL28333053 | 0.81 | KMT2A (0.56) | BTKEGFRITK | |
| SCHEMBL2331315 | 0.78 | CHEK2 (0.47) | MERTKSPRBTK | |
| SCHEMBL19665640 | 0.78 | HSD11B1 (0.47) | JAK3JAK2 | |
| SCHEMBL22439077 | 0.76 | KMT2A (0.45) | AXLJAK3JAK2BTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324226-B2 | Therapeutic oxy-phenyl-aryl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| EP-2227460-B1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| EP-2227460-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009053694-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CHEK2, CHEK1, PLK1 | AXL 750/4885IRAK1 1122/4885IRAK4 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.